Debt-to-equity of Fulcrum Therapeutics, Inc. from 31 Mar 2020 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Fulcrum Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2020 to 31 Dec 2025.
  • Fulcrum Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 6.3%, a 21% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Fulcrum Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 6.3% -1.7% -21% 31 Dec 2025
Q3 2025 7.1% -1.4% -17% 30 Sep 2025
Q2 2025 7.2% -1.5% -17% 30 Jun 2025
Q1 2025 7.4% -1.8% -19% 31 Mar 2025
Q4 2024 8% -1% -11% 31 Dec 2024
Q3 2024 8.5% -1.3% -13% 30 Sep 2024
Q2 2024 8.7% -1.7% -17% 30 Jun 2024
Q1 2024 9.2% -3.8% -29% 31 Mar 2024
Q4 2023 9% -6.5% -42% 31 Dec 2023
Q3 2023 9.8% -4.9% -33% 30 Sep 2023
Q2 2023 10% -3.9% -27% 30 Jun 2023
Q1 2023 13% -1.4% -9.8% 31 Mar 2023
Q4 2022 16% +0.25% +1.6% 31 Dec 2022
Q3 2022 15% -5.6% -28% 30 Sep 2022
Q2 2022 14% -15% -50% 30 Jun 2022
Q1 2022 14% -13% -48% 31 Mar 2022
Q4 2021 15% -15% -49% 31 Dec 2021
Q3 2021 20% -7.5% -27% 30 Sep 2021
Q2 2021 29% +7% +32% 30 Jun 2021
Q1 2021 27% -22% -44% 31 Mar 2021
Q4 2020 30% 31 Dec 2020
Q3 2020 28% 30 Sep 2020
Q2 2020 22% 30 Jun 2020
Q1 2020 49% 31 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.